Article Sidebar

Submitted
July 9, 2023
Published
June 30, 2023
Download
PDF
Statistic
Read Counter : 172 Download : 126

Main Article Content

Abstract

Chronic obstructive pulmonary disease (COPD) is an obstructive pulmonary disease due to inflammatory processes of the respiratory tract and lung parenchyma. In some cases of COPD, changes in the pulmonary vessels are found which are not uncommon, causing impaired gas exchange and causing pulmonary hypertension which is associated with increased morbidity and mortality. Pulmonary hypertension is an increase in the mean pulmonary artery pressure (Pulmonary Arterial Pressure) greater than or equal to 25 mmHg at rest as assessed by a right heart catheterization procedure. Pulmonary hypertension (HP) can exacerbate the occurrence of COPD where HP patients with COPD must receive optimal COPD management according to GOLD guidelines. Pulmonary hypertension can be caused by a variety of conditions which WHO divides into five major groups. Pulmonary hypertension in patients with COPD belongs to the third group. The pathophysiology of pulmonary hypertension in patients with hypoxia or chronic lung disease is caused by tunica media hypertrophy and tunica intima proliferation leading to distal pulmonary artery obstruction. Clinical and physical symptoms in HP patients in COPD usually overlap. If HP is suspected, echocardiography is the best initial examination. Definitive diagnosis obtained through right heart catheterization. In contrast to idiopathic pulmonary hypertension, examination of the vasoreactivity of blood vessels during right heart catheterization in this group is not recommended. The goal of therapy is improvement of clinical symptoms, hemodynamic status, right ventricular function and ultimately increase in quality of life and life expectancy. Oxygen therapy is the main therapy in HP and COPD after medical therapy. Providing adequate therapy for HP with COPD is expected to provide good outcomes for patients.

Keywords

pulmonary hypertension COPD management

Article Details

License

Copyright (c) 2023 IDA BAGUS ADITYA NUGRAHA, IDA AYU PUTU PADMI DEVIANI

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
NUGRAHA, I. B. A., & DEVIANI, I. A. P. P. (2023). A MANAGEMENT OF PULMONAL HYPERTENSION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Jurnal Kedokteran Raflesia, 9(1), 36–47. https://doi.org/10.33369/juke.v9i1.28838
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Elwing J, Panos RJ. Pulmonary hypertension associated with COPD. Int J Chron Obstruct Pulmon Dis.2008;3(1):55–70.
  2. Jyothula S, Safdar Z. Update on pulmonary hypertension complicating chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2009;4:351–63.
  3. McLaughlin V V, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College . Circulation. 2019;119:2250–94.
  4. Chaouat a, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J. 2008;32:1371–85.
  5. Shujaat A, Bajwa A a, Cury JD. Pulmonary hypertension secondary to COPD. Pulm Med. 2012;2012:203952.
  6. Todd M,Kolb, Hassoun P. Right ventricular dysfunction in Chronic Lung Disease.Cardiol Clin.2013;30:243–56.
  7. Minai O a, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest. 2010;137:39S–51S.
  8. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery J-L, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS).Internat. Eur Heart J. 2009;30:2493–537.
  9. Global Initiative for Chronic Obstructive Lung. 2023. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html
  10. Stamm J a, Risbano MG, Mathier M a. Overview of current therapeutic approaches for pulmonary hypertension. Pulm Med.2011;1:138-59.
  11. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc.2005;2:20–2.
  12. Weitzenblum E, Kessler R, Oswald M, Fraisse P. Medical treatment of pulmonary hypertension in chronic lung disease. Eur Respir J.1994;7:148–52.
  13. Hopkins N, McLoughlin P. The structural basis of pulmonary hypertension in chronic lung disease: remodelling, rarefaction or angiogenesis? J Anat. 2002;201:335–48.
  14. Nef HM, Möllmann H, Hamm C, Grimminger F, Ghofrani H-A. Pulmonary hypertension: updated classification and management of pulmonary hypertension. Heart.2010;96:552–9.
  15. Natarajan R. Recent trends in pulmonary arterial hypertension. Lung India. 2011 Jan;28:39–48.
  16. Solidoro P,Boffini M,Lacedonia D.Pulmonary hypertension in COPD and Lung Transplantation: Timing and Procedure. Minerva Med. 2014;105:1–7.
  17. Ghofrani H-A, Galiè N, Grimminger F, Grünig E, Humbert M, Jing Z-C, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330–40.
  18. Rubin L,Hopskin W,Mandel,J.Overview Pulmonary hypertension in Adult. Uptodate 2023. http://www.uptodate.com/contents/overview-of-pulmonary-hypertension-in-adults